PYC Therapeutics Limited ( (AU:PYC) ) has issued an announcement.
PYC Therapeutics has received regulatory approval to begin human trials for its PKD drug candidate, PYC-003. The trials will start with a Single Ascending Dose study involving healthy volunteers and PKD patients in Australia, aiming to generate initial safety and efficacy data by 2025. This development marks a significant step in addressing the unmet medical need for PKD treatments and could enhance PYC’s position in the biotechnology industry.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing precision therapies for genetic diseases that currently have no treatment options available. The company is advancing a drug candidate designed to address Autosomal Dominant Polycystic Kidney Disease (PKD), a severe condition affecting millions worldwide.
YTD Price Performance: -4.92%
Average Trading Volume: 384,361
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$585.6M
For an in-depth examination of PYC stock, go to TipRanks’ Stock Analysis page.